The growing awareness of cardiac dysfunction by cancer treatment has led to the emerging field of Cardio-Oncology. However, there are no guidelines in terms of how to prevent and treat the new cardiotoxicity in cancer survivors due to the limited experimental assays. Dr. Cheng is a computational biologist by training, with expertise in analyzing, visualizing, and mining data from real world (e.g., electronic health records, and health care claims) and experiments that profile the molecular state of human cells and tissues by interactomics, transcriptomics, genomics, proteomics, and metabolomics for personalized drug discovery and precise patient care. The primary goal of Dr. Cheng’s lab is to combine tools from genomics, network medicine, bioinformatics, computational biology, chemical biology, and experimental pharmacology and systems biology assays (e.g., single cell sequencing and iPS-derived cardiomyocytes), to address the challenging questions toward understanding of various human complex diseases (e.g., cardio-oncology, pulmonary vascular diseases, and cancer), which could have a major impact in identifying novel real-world data-driven diagnostic biomarkers and therapeutic targets for precision medicine.
Assistant Staff, Genomic Medicine Institute, Cleveland Clinic